



CHANDAN HEALTHCARE LIMITED

Reg. Off. Add: Biotech Park, Sector-G, Jankipuram, Kursi Road, Lucknow-226021

CIN: U85110UP2003PLC193493

TELNO.: -8069366666 **Email:** secretarial@chandan.co.in

www.chandandiagnostic.com

Date: May 27, 2025

To,
The Listing Department
National Stock Exchange of India Ltd.
Exchange Plaza, Plot no. C/1, G Block,
Bandra- Kurla Complex, Bandra (East),
Mumbai - 400 051

Symbol: CHANDAN

Ref: Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Sub: Outcome of Board meeting held on Tuesday, May 27, 2025, at 12:30 P.M. (IST)

Dear Sir/Madam,

Pursuant to Regulation 30 and other applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that the Board of Directors of Chandan Healthcare Limited (“the Company”) at their meeting held today on Tuesday, May 27, 2025, has inter-alia, considered and approved:

- 1.** Audited Financial Results (Standalone & Consolidated) of the Company for the Half Year and Financial Year ended March 31, 2025, along with the Audit Report of the Auditors thereon pursuant to Regulation 33 of SEBI (Listing Obligations & Disclosures Requirements) Regulations, 2015;

Accordingly, pursuant to Regulations 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”), we are enclosing the following:

- i. Statements showing the Audited Standalone Financial Results for the half year and Financial Year ended March 31, 2025; (**‘Annexure – A1’**).
- ii. Statements showing the Audited Consolidated Financial Results for the half year and Financial Year ended March 31, 2025; (**‘Annexure – A2’**).
- iii. Audit Report on the Standalone Financial Results for the half year and Financial Years ended March 31, 2025; (**‘Annexure – A3’**).
- iv. Audit Report on the Consolidated Financial Results for the half year and Financial Year ended March 31, 2025; (**‘Annexure – A4’**).

In Compliance with Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended by the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) (Amendment) Regulations, 2016, vide notification no. SEBI/LAD-NRO/GN/2016- 17/001 dated 25th May, 2016 and Circular no CIR/CFD/CMD/56/2016 dated 27th May 2016, we hereby state that the Statutory Auditors of the Company, M/s MSNT & ASSOCIATES LLP, Chartered Accountants (FRN: 018542C) have issued an Audit Report with an unmodified opinion on the Audited Financial Results of



CHANDAN HEALTHCARE LIMITED

Reg. Off. Add: Biotech Park, Sector-G, Jankipuram, Kursi Road, Lucknow-226021

CIN: U85110UP2003PLC193493

TELNO.: -8069366666 **Email:** secretarial@chandan.co.in

www.chandandiagnostic.com

the Company for the half year and the Year ended 31st March, 2025. **Form A** in respect of the same is enclosed herewith as '**Annexure B**'.

The Board meeting commenced at 12:30 PM and concluded at 08:45 P.M.

Kindly take the above information on record. The above information is also available on the Company's website at www.chandandiagnostic.com.

Thanking you,

Yours sincerely,

For Chandan Healthcare Limited

Rajeev Nain

Company Secretary & Compliance Officer

Encl.: as above



Company name :- Chandan Healthcare Limited

CIN :- U85110UP2003PLC193493

Registered address :- Biotech Park, Sector G, Kursi road, Jankipuram, Lucknow, Uttar Pradesh, India, 226021.

(All amounts are in ₹ nearest lakhs or decimals thereof, unless otherwise stated)

Audited Standalone Statement of Financial Results for the year ended 31st March, 2025

Particulars	Half Year Ended			Year Ended	
	31st March, 2025	30th September, 2024	31st March, 2024	31st March, 2025	31st March, 2024
	Audited	Unaudited	Audited	Audited	Audited
I. Revenue from operations	6,716.54	6,199.88	5,193.49	12,916.42	9,987.48
II. Other income	68.14	62.89	51.78	131.03	99.57
III. Total revenue(I+II)	6,784.67	6,262.78	5,245.27	13,047.45	10,087.05
IV. Expenses:					
Cost of material consumed	801.94	740.25	567.64	1,542.19	1,091.62
Purchase of stock-in-trade	232.24	214.37	135.71	446.61	260.98
Change in inventories of finished goods, work-in-progress and stock-in-trade.	(9.97)	(9.21)	(19.35)	(19.18)	(37.22)
Employee benefits expense	1,736.05	1,602.51	1,584.01	3,338.56	3,046.18
Finance Costs	185.55	171.28	109.87	356.83	211.28
Depreciation and amortisation expense	333.96	308.28	174.76	642.24	336.07
Other expenses	2,040.30	1,883.35	1,602.63	3,923.65	3,081.99
Total expenses (IV)	5,320.07	4,910.83	4,155.27	10,230.90	7,990.90
V. Profit/(loss) before exceptional & extraordinary items and tax (III-IV)	1,464.61	1,351.94	1,090.00	2,816.55	2,096.15
VI. Exceptional items	-	-	-	-	-
VII. Profit/(loss) before extraordinary items and tax (V-VI)	1,464.61	1,351.94	1,090.00	2,816.55	2,096.15
VIII. Extraordinary items	-	-	-	-	-
IX. Profit/(loss) before tax (VII- VIII)	1,464.61	1,351.94	1,090.00	2,816.55	2,096.15
X. Tax expense of continuing operation -					
Current tax	364.07	336.07	255.15	700.14	490.68
Deferred tax	20.08	18.53	1.99	36.61	3.82
Tax expense(X)	384.15	354.60	257.14	736.75	494.50
XI. Profit/(loss) for the period from continuing operations(after tax) (IX-X)	1,080.46	997.34	832.86	2,077.80	1,601.65
XII. Profit/(loss) from discontinuing operations	-	-	-	-	-
XIII. Tax expense of discontinuing operations	-	-	-	-	-
XIV. Profit/(loss) from discontinuing operations (after tax) (XII-XIII)	-	-	-	-	-
XV. Share of (profit)/ loss transferred to minority interest	-	-	-	-	-
XVI. Profit/ (Loss) after tax attributable to owners of the company (XI+XIV+XV)	1,080.46	997.34	832.86	2,077.80	1,601.65
XVII. Earnings per equity share					
(1) Basic	5.25	4.85	4.16	10.10	8.01
(2) Diluted	5.25	4.85	4.16	10.10	8.01

As per our report of even date attached
For M/s Msnt & Associates LLP
Chartered accountants
Firm registration no. :- 018542C/C400322

Navodit tyagi
Partner
Membership no. :- 533375
UDIN no. :- 25533375BMOKNM2014
Place :- Noida
Date :- 27th May 2025



For & on behalf of the board of directors
Chandan Healthcare Limited

(Signature)
Amar Singh
Managing director
Din. :- 01096328
Place :- Lucknow
Date :- 27th May 2025



Company name :- Chandan Healthcare Limited

CIN :- U85110UP2003PLC193493

Registered address :- Biotech Park, Sector G, Kursi road, Jankipuram, Lucknow, Uttar Pradesh, India, 226021.

(All amounts are in ₹ nearest lakhs or decimals thereof, unless otherwise stated)

Audited Standalone Statement of Assets & Liabilities as at 31st March, 2025

Particulars	Figures as at the end of 31st March, 2025	Figures as at the end of 31st March, 2024
I. EQUITY AND LIABILITIES		
(1) Shareholder's funds		
(a) Share capital	2,445.21	2,000.00
(b) Reserves and surplus	9,626.41	2,066.68
(c) Money received against share warrants	-	-
(2) Share application money pending allotment	-	-
(3) Minority interest	-	-
(4) Non-current liabilities		
(a) Long-term borrowings	2,214.46	1,217.56
(b) Deferred tax liabilities(net)	190.33	151.72
(c) Other long-term liabilities	2.45	0.45
(d) Long term provisions	313.01	283.66
(5) Current liabilities		
(a) Short-term borrowings	1,105.92	1,690.28
(b) Trade payables		
(i) Total outstanding dues of micro & small enterprises.	662.44	220.70
(ii) Total outstanding dues of creditors other than micro & small enterprises.	371.54	391.34
(c) Other current liabilities	693.47	1,255.38
(d) Short term provisions	65.11	34.07
TOTAL	17,690.35	9,311.84
II. ASSETS		
(1) Non-current assets		
(a) Property, plant & equipments & intangible assets		
(i) Property, plant & equipments	7,148.48	4,352.80
(ii) Intangible assets	-	-
(iii) Capital work in progress	410.12	-
(iv) Intangible assets under development	-	-
(b) Non-current investments	1,031.54	1,031.54
(c) Deferred tax assets(net)	-	-
(d) Long-term loans and advances	53.90	112.94
(e) Other non-current assets	1,735.64	325.30
(2) Current assets		
(a) Current investments	-	222.97
(b) Inventories	1,711.99	645.81
(c) Trade receivables	3,131.03	2,185.60
(d) Cash and bank balances	603.10	53.14
(e) Short-term loans and advances	762.98	231.43
(f) Other current assets	1,101.57	150.31
TOTAL	17,690.35	9,311.84

As per our report of even date attached
For M/s Msnt & Associates LLP
Chartered accountants
Firm registration no. :- 018542C/C400322

Navodit tyagi
Partner

Membership no. :- 533375
UDIN no. :- 25533375BMOKNM2014
Place :- Noida
Date :- 27th May 2025



For & on behalf of the board of directors
Chandan Healthcare Limited

Amar singh
Managing director
Din. :- 01096328
Place :- Lucknow
Date :- 27th May 2025



Company name :- Chandan Healthcare Limited

CIN :- U85110UP2003PLC193493

Registered address :- Biotech Park, Sector G, Kursi road, Jankipuram, Lucknow, Uttar Pradesh, India, 226021.

(All amounts are in ₹ nearest lakhs or decimals thereof, unless otherwise

Audited Standalone Statement of Cash flow for the year ended 31st March, 2025

Particulars	Figures for the year ended 31st March, 2025	Figures for the year ended 31st March, 2024
A. Cash flow arising from operating activities		
Profit / (Loss) before tax	2,816.55	2,096.15
Adjustments related to non-cash & non operating transactions:		
Non cash transactions		
Depreciation & amortisation of fixed assets	642.24	336.07
Bad Debts & Balances written off/written back	(82.47)	3.52
Re-measurement (gains) / loss on defined benefit plans	71.77	89.77
Provision for doubtful debts	15.28	5.24
Provision for obsolete inventories	10.10	6.26
Non operating transactions		
Interest on borrowing	341.10	199.81
Interest income	(45.32)	(24.50)
Dividend income	-	(68.87)
Operating profit/(loss) before working capital changes	3,769.25	2,643.43
Adjustment for change in working capital:		
(Increase) / Decrease in inventories	(1,076.28)	(616.26)
(Increase) / Decrease in trade receivables	(878.23)	(851.98)
(Increase) / Decrease in other current assets	(2,834.11)	64.99
(Decrease) / Increase in trade payables	421.94	(1,148.30)
(Decrease) / Increase in other current liabilities	(532.68)	851.51
Net cash (used in) / generated from operating activities	(1,130.11)	943.39
Income taxes refund / (paid), net	(738.75)	(358.84)
Net cash flow from operating activities(A)	(1,868.86)	584.55
B. Cash flow arising from investing activities		
Sale/(Purchase) of tangible and intangible assets	(3,848.04)	(1,915.73)
Sale/(Purchase) of non current & current investments	222.97	286.17
Interest income	45.32	24.50
Dividend income	-	68.87
Net cash flow from investing activities(B)	(3,579.75)	(1,536.18)
C. Cash Flow Arising From Financing Activities		
Proceeds from issuance of share capital	6,227.13	-
Proceeds from/(Payment of) long term & short term borrowings	412.54	1,250.46
Finance cost paid (including processing fees)	(341.10)	(199.81)
Dividend paid	(300.00)	(200.00)
Net cash flow from financing activities(C)	5,998.57	850.65
Net increase/decrease in cash or cash equivalents(A+B+C)	549.96	(100.98)
Cash and cash equivalents at the beginning of the period	53.14	154.12
Cash and cash equivalents at the end of the period	603.10	53.14

As per our report of even date attached
For M/s Msnt & Associates LLP
Chartered accountants

Navodit tyagi
Partner

Membership no. :- 533375
UDIN no. :- 25533375BMOKNM2014
Place :- Noida
Date :- 27th May 2025



For & on behalf of the board of directors
Chandan Healthcare Limited

Amar singh
Managing director
Din. :- 01096328
Place :- Lucknow
Date :- 27th May 2025



Company name :- Chandan Healthcare Limited

CIN :- U85110UP2003PLC193493

Registered address :- Biotech Park, Sector G, Kursi road, Jankipuram, Lucknow, Uttar Pradesh, India, 226021.

(All amounts are in ₹ nearest lakhs or decimals thereof, unless otherwise stated)

Audited Consolidated Statement of Financial Results for the year ended 31st March, 2025

Particulars	Half Year Ended			Year Ended	
	31st March, 2025	30th September, 2024	31st March, 2024	31st March, 2025	31st March, 2024
	Audited	Unaudited	Audited	Audited	Audited
I. Revenue from operations	11,966.28	11,045.80	9,182.69	23,012.08	17,659.01
II. Other income	106.67	98.47	63.53	205.14	122.18
III. Total revenue(I+II)	12,072.95	11,144.27	9,246.22	23,217.22	17,781.19
IV. Expenses:					
Cost of material consumed	803.86	742.02	576.00	1,545.88	1,107.69
Purchase of stock-in-trade	4,939.03	4,559.11	3,765.72	9,498.14	7,241.77
Change in inventories of finished goods, work-in-progress and stock-in-trade.	(146.81)	(135.51)	(137.52)	(282.32)	(264.47)
Employee benefits expense	2,020.78	1,865.33	1,842.05	3,886.11	3,542.40
Finance Costs	237.92	219.61	143.12	457.53	275.23
Depreciation and amortisation expense	350.73	323.75	177.01	674.48	340.40
Other expenses	2,200.08	2,030.85	1,763.89	4,230.93	3,392.10
Total expenses (IV)	10,405.59	9,605.16	8,130.26	20,010.75	15,635.12
V. Profit/(loss) before exceptional & extraordinary items and tax (III-IV)	1,667.36	1,539.11	1,115.96	3,206.47	2,146.07
VI. Exceptional items	-	-	-	-	-
VII. Profit/(loss) before extraordinary items and tax (V-VI)	1,667.36	1,539.11	1,115.96	3,206.47	2,146.07
VIII. Extraordinary items	-	-	-	-	-
IX. Profit/(loss) before tax (VII- VIII)	1,667.36	1,539.11	1,115.96	3,206.47	2,146.07
X. Tax expense of continuing operation -					
Current tax	431.90	398.68	265.49	830.58	510.56
Deferred tax	12.66	11.68	(0.04)	24.34	(0.07)
Tax expense(X)	444.56	410.36	265.45	854.92	510.49
XI. Profit/(loss) for the period from continuing operations(after tax) (IX-X)	1,222.81	1,128.74	850.50	2,351.55	1,635.58
XII. Profit/(loss) from discontinuing operations	-	-	-	-	-
XIII. Tax expense of discontinuing operations	-	-	-	-	-
XIV. Profit/(loss) from discontinuing operations (after tax) (XII-XIII)	-	-	-	-	-
XV. Share of (profit)/ loss transferred to minority interest	(69.90)	(64.53)	(4.08)	(134.43)	(7.85)
XVI. Profit/ (Loss) after tax attributable to owners of the company (XI+XIV+XV)	1,152.90	1,064.22	846.42	2,217.12	1,627.73
XVII. Earnings per equity share					
(1) Basic	5.60	5.17	4.23	10.78	8.14
(2) Diluted	5.60	5.17	4.23	10.78	8.14

As per our report of even date attached
For M/s Msnt & Associates LLP
Chartered accountants
Firm registration no. :- 018542C/C400322

Navodit tyagi
Partner
Membership no. :- 533375
UDIN no. :- 25533375BMOKNL8635
Place :- Noida
Date :- 27th May 2025



For & on behalf of the board of directors
Chandan Healthcare Limited

Amar Singh
Managing director
Din. :- 01096328
Place :- Lucknow
Date :- 27th May 2025



Company name :- Chandan Healthcare Limited

CIN :- U85110UP2003PLC193493

Registered address :- Biotech Park, Sector G, Kursi road, Jankipuram, Lucknow, Uttar Pradesh, India, 226021.

(All amounts are in ₹ nearest lakhs or decimals thereof, unless otherwise stated)

Audited Consolidated Statement of Cash Flow for the year ended 31st March, 2025

Particulars	Consolidated figures for the year ended 31st March, 2025	Consolidated figures for the year ended 31st March, 2024
A. Cash flow arising from operating activities		
Profit / (Loss) before tax	3,206.47	2,146.07
Adjustments related to non-cash & non operating transactions:		
Non cash transactions		
Depreciation & amortisation of fixed assets	674.48	340.40
Bad Debts & Balances written off/written back	(124.78)	3.52
Re-measurement (gains) / loss on defined benefit plans	84.27	89.77
Provision for doubtful debts	15.35	5.24
Provision for obsolete inventories	26.72	6.26
Non operating transactions		
Interest on borrowing	441.79	260.72
Interest income	(72.98)	(24.50)
Dividend income	-	(75.98)
Operating profit/(loss) before working capital changes	4,251.32	2,751.48
Adjustment for change in working capital:		
(Increase) / Decrease in inventories	(1,339.42)	(843.51)
(Increase) / Decrease in trade receivables	(1,699.38)	(295.98)
(Increase) / Decrease in other current assets	(2,929.24)	(571.10)
(Decrease) / Increase in trade paybles	543.05	(1,350.13)
(Decrease) / Increase in other current liabilities	(876.75)	911.49
Net cash (used in) / generated from operating activities	(2,050.42)	602.25
Income taxes refund / (paid), net	(854.92)	(490.54)
Net cash flow from operating activities(A)	(2,905.34)	111.71
B. Cash flow arising from investing activities		
Sale/(Purchase) of tangible and intangible assets	(3,870.48)	(1,954.19)
Sale/(Purchase) of non current & current investments	222.97	370.97
Interest income	72.98	24.50
Dividend income	-	75.98
Net cash flow from investing activities(B)	(3,574.53)	(1,482.73)
C. Cash Flow Arising From Financing Activities		
Proceeds from issuance of share capital	6,227.11	-
Proceeds from/(Payment of) long term & short term borrowings	1,225.27	2,065.77
Finance cost paid (including processing fees)	(441.79)	(260.72)
Dividend paid	(300.00)	(248.45)
Net cash flow from financing activities(C)	6,710.59	1,556.60
Net increase/decrease in cash or cash equivalents(A+B+C)	230.72	185.58
Cash and cash equivalents at the beginning of the period	389.99	204.41
Cash and cash equivalents at the end of the period	620.71	389.99

As per our report of even date attached

For M/s Msmt & Associates LLP
Chartered accountants

Navodil Tyagi
Partner

Membership no. :- 533375

UDIN no. :- 25533375BMOKNL8635

Place :- Noida

Date :- 27th May 2025



For & on behalf of the board of directors
Chandan Healthcare Limited

Amar Singh
Managing director
Din. :- 01096328
Place :- Lucknow
Date :- 27th May 2025



Company name :- Chandan Healthcare Limited
CIN :- U85110UP2003PLC193493

Registered address :- Biotech Park, Sector G, Kursi road, Jankipuram, Lucknow, Uttar Pradesh, India, 226021.

(All amounts are in ₹ nearest lakhs or decimals thereof, unless otherwise stated)

Audited Consolidated Statement of Assets & Liabilities as at 31st March, 2025

Particulars	Consolidated figures as at the end of 31st March, 2025	Consolidated figures as at the end of 31st March, 2024
I. EQUITY AND LIABILITIES		
(1) Shareholder's funds		
(a) Share capital	2,445.21	2,000.00
(b) Reserves and surplus	9,815.13	2,116.11
(c) Money received against share warrants	-	-
(2) Share application money pending allotment	-	-
(3) Minority interest	380.45	246.02
(4) Non-current liabilities		
(a) Long-term borrowings	2,214.46	1,217.56
(b) Deferred tax liabilities(net)	172.29	139.35
(c) Other long-term liabilities	2.45	0.45
(d) Long term provisions	343.69	305.75
(5) Current liabilities		
(a) Short-term borrowings	2,601.92	2,373.55
(b) Trade payables		
(i) Total outstanding dues of micro & small enterprises.	1,008.76	701.77
(ii) Total outstanding dues of creditors other than micro & small enterprises.	1,569.52	1,249.19
(c) Other current liabilities	438.78	1,422.77
(d) Short term provisions	69.04	34.68
TOTAL	21,061.70	11,807.20
II. ASSETS		
(1) Non-current assets		
(a) Property, plant & equipments & intangible assets		
(i) Property, plant & equipments	7,191.99	4,406.11
(ii) Intangible assets	443.28	443.28
(iii) Capital work in progress	410.12	-
(iv) Intangible assets under development	-	-
(b) Non-current investments	114.75	337.72
(c) Deferred tax assets(net)	-	-
(d) Long-term loans and advances	54.08	119.55
(e) Other non-current assets	1,816.52	367.47
(2) Current assets		
(a) Current investments	-	-
(b) Inventories	3,137.07	1,824.37
(c) Trade receivables	4,669.74	2,860.93
(d) Cash and bank balances	620.71	389.99
(e) Short-term loans and advances	960.03	821.54
(f) Other current assets	1,643.41	236.24
TOTAL	21,061.70	11,807.20

As per our report of even date attached
For M/s Msnt & Associates LLP
Chartered accountants
Firm registration no. :- 018542C/C400322

Navedit tyagi

Partner

Membership no. :- 533375

UDIN no. :- 25533375BMOKNL8635

Place :- Noida

Date :- 27th May 2025



For & on behalf of the board of directors

Chandan Healthcare Limited

Amar Singh
Managing director

Din. :- 01096328

Place :- Lucknow

Date :- 27th May 2025





MSNT & ASSOCIATES LLP

CHARTERED ACCOUNTANTS

Independent Auditor's Report on Half Yearly and to Date Audited Standalone financial results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

To,
The Board of Directors,
Chandan Healthcare Limited,
Lucknow

Report on the audit of the Standalone Financial Results

Opinion

We have audited the accompanying statement of half yearly and year to date standalone financial results of M/s. *Chandan Healthcare Limited* (the "Company") for the half year ended March 31, 2025, and for the year ended March 31, 2025 (the "Statement"), attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, the Statement.

- I. Is presented in accordance with the requirements of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended; and
- II. gives a true and fair view in conformity with the recognition and measurement principles laid down in the Indian Accounting Standards and other accounting principles generally accepted in India of the net profit and other comprehensive profit and other financial information for the half year ended March 31, 2025, as well as year to date results for the period from April 1 2024 to 31 March 2025.

Basis for Opinion

We conducted our audit in accordance with the Standard on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 (the Act). Our responsibility under those Standards are described in the Auditor's Responsibility for the Audit of the Standalone Financial Results section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statement under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis of our opinion.



📍 : **Head Office:** - A-40, I-Thum, Tower-B, 10th Floor, Unit No. 1033, Sector 62, Noida-201005.
Branch Office: - 239, Satra Plaza, Sector-19 D, Palm Beach Road, Vashi, Navi Mumbai-400703.
☎ : CA Saurabh Tyagi: 7718802884, CA Navodit Tyagi: 9167436404, CA Manoj Modi: 9022059201.
✉ : saurabh@msnt.in navodit@msnt.in manoj@msnt.in

Management's Responsibilities for the Standalone Financial Results

The Statement have been prepared on the basis of the standalone financial statements. The Company's Board of Directors are responsible for the preparation of the Statement that give a true and fair view of the net profit and other comprehensive profit and other financial information in accordance with the recognition and measurement principles laid down in Indian Accounting Standard prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone financial results, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Standalone Financial Results

Our objectives are to obtain reasonable assurance about whether the statement as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial results. As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, Under Section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the Company has adequate internal financial control with reference to financial statements in place and operating effectiveness of such control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to



continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.

- Evaluate the overall presentation, structure and content of the statement, including the disclosures, and whether the financial results represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matter

The Statement includes the results for the half year ended March 31, 2025, being the balancing figure between the audited figures in respect of the full financial year ended March 31, 2025, and the unaudited year – to date figures up to the First half year of the current financial year as per books of accounts.

As Per MCA Notification dated 16th February 2015, companies whose shares are listed on SME exchange as referred to in chapter XB of the SEBI (Issue of capital & disclosures requirement) regulation 2009 are exempted from the compulsory requirement of adoption of IND AS. As the company is covered under the exempted category, it has not adopted IND AS for the preparation of financial statement.

Figures for the previous periods/year have been regrouped, restated and/or reclassified whenever considered necessary to make them comparable to the current periods.

Our opinion on the statement is not modified in respect of the above matters with respect to our reliance on the work done and the reports of the other auditors and the financial information certified by the Board of Directors.

For MSNT & ASSOCIATES LLP

Chartered Accountants

Firm Registration No.018542C/C400322



Navodit Tyagi

Partner

Membership No.-533375

UDIN No: 25533375BMOKNM2014

Place: Noida

Date: 27/05/2025





MSNT & ASSOCIATES LLP

CHARTERED ACCOUNTANTS

Independent Auditor's Report on Half Yearly and Year to Date Audited Consolidated financial results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

To,
The Board of Directors,
Chandan Healthcare Limited,
Lucknow

Report on the audit of the Consolidated Financial Results

Opinion

We have audited the accompanying Statement of half yearly and year to date Consolidated Financial Results of *M/s. Chandan Healthcare Limited* (hereinafter referred to as the "Holding company") and its subsidiaries (holding company and its subsidiaries together referred to as "the Group"), ("the Statement"), being submitted by the holding company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, and based on the consideration of the reports of the other auditors on separate financial statements/ financial information of subsidiaries, the Statement:

- a) includes the results of the following entities:
 - I. Chandan Pharmacy Limited.
 - II. Chandan Diagnostic Limited.
 - III. Indira Diagnostic Centre & Blood Bank Limited.
- b) is presented in accordance with the requirements of Regulation 33 of the Listing Regulations, as amended; and
- c) gives a true and fair view, in conformity with the applicable accounting standards, and other accounting principles generally accepted in India, of consolidated net profit after tax and other comprehensive profit and other financial information of the Group for the half year ended March 31, 2025, and for the period from April 01, 2024 to March 31, 2025.



 : **Head Office:** - A-40, I-Thum, Tower-B, 10th Floor, Unit No. 1033, Sector 62, Noida-201005.
Branch Office: - 239, Satra Plaza, Sector-19 D, Palm Beach Road, Vashi, Navi Mumbai-400703.
 : CA Saurabh Tyagi: 7718802884, CA Navodit Tyagi: 9167436404, CA Manoj Modi: 9022059201.
 : saurabh@msnt.in navodit@msnt.in manoj@msnt.in

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 (the Act). Our responsibilities under those Standards are further described in the *Auditor's Responsibilities for the Audit of the Consolidated Financial Results* section of our report. We are independent of the Group in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us and other auditors in terms of their reports referred to in "Other Matter" paragraph below, is sufficient and appropriate to provide a basis for our opinion.

Management's Responsibilities for the Consolidated Financial Results

The Statement, which is the responsibility of the Holding Company's management and has been approved by the Holding Company's Board of Directors, has been prepared on the basis of the consolidated annual financial statements. The Holding Company's Board of Directors are responsible for the preparation and presentation of Statement that give a true and fair view of the net profit and other comprehensive profit and other financial information of the Group in accordance with the recognition and measurement principles laid down in Indian Accounting Standard prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations.

The respective Board of Directors of the companies included in the Group, are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Group and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the Statement by the Directors of the Holding Company, as aforesaid.

In preparing the Statement, the respective Board of Directors of the companies included in the Group entities are responsible for assessing the ability of the Group to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of Directors either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the companies included in the Group are responsible for overseeing the financial reporting process of the Group.

Auditor's Responsibilities for the Audit of the Consolidated Financial Results

Our objectives are to obtain reasonable assurance about whether the Statement as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users on the basis of these consolidated financial results.



As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal control. Under Section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Group to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the statement, including the disclosures, and whether the statement represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the financial results/financial information of the entities within the Group to express an opinion on the Statement. We are responsible for the direction, supervision and performance of the audit of financial information of such entities included in the Statement of which we are the independent auditors. For the other entities included in the Statement, which have been audited by other auditors, such other auditors remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion.

We communicate with those charged with governance of the Holding Company regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the Listing Regulations, as amended, to the extent applicable.



Other Matters

The consolidated annual financial results include the audited financial results of three subsidiaries. The financial statements of these subsidiaries reflect the Group's share of total assets of Rs. 4,356.78 lakhs (before consolidation adjustments) as at 31st March, 2025, the Group's share of total revenue from operations of Rs. 10,124.83 lakhs (before consolidation adjustments), the Group's share of total income of Rs. 273.84 lakhs (before consolidation adjustments), and the Group's share of net cash outflows of Rs. 300.89 lakhs (before consolidation adjustments) for the year ended on that date. Out of these three subsidiaries, the financial statements of **Chandan Pharmacy Limited** have been audited by us, while the financial statements of the other two subsidiaries have been audited by their respective independent auditors. The independent auditors' reports on the financial statements of these two entities have been furnished to us by the management, and our opinion on the consolidated annual financial results, in so far as it relates to the amounts and disclosures included in respect of these entities, is based solely on the reports of such auditors and the procedures performed by us as stated in the paragraph above.

The Statement includes the results for the half year ended March 31, 2025, being the balancing figure between the audited figures in respect of the full financial year ended March 31, 2025, and the unaudited year – to date figures up to the first half year of the current financial year as per books of accounts.

As Per MCA Notification dated 16th February 2015, companies whose shares are listed on SME exchange as referred to in chapter XB of the SEBI (Issue of capital & disclosures requirement) regulation 2009 are exempted from the compulsory requirement of adoption of IND AS. As the company is covered under the exempted category, it has not adopted IND AS for the preparation of financial statement.

Figures for the previous periods/year have been regrouped, restated and/or reclassified whenever considered necessary to make them comparable to the current periods.

Our opinion on the statement is not modified in respect of the above matters with respect to our reliance on the work done and the reports of the other auditors and the financial information certified by the Board of Directors.

For MSNT & ASSOCIATES LLP

Chartered Accountants

Firm Registration No.018542C/C400322



Navodit Tyagi

Partner

Membership No.-533375

UDIN No: 25533375BMOKNL8635

Place: Noida

Date: 27/05/2025



**CHANDAN HEALTHCARE LIMITED**

Reg. Off. Add: Biotech Park, Sector-G, Jankipuram, Kursi Road, Lucknow-226021

CIN: U85110UP2003PLC193493

TELNO.: -8069366666 Email: secretarial@chandan.co.in

www.chandandiagnostic.com**Annexure B****Statement on Impact of Audit Qualification (for audit report with unmodified opinion) submitted along with Annual Audited Financial Results (Standalone)**

Statement of impact of Audit Qualifications for the financial year ended March 31, 2025 (Regulations 33 of the SEBI (LODR) Amendment regulations, 2016)				
	SL No	Particulars	Audited Figures (as reported before adjusting for the qualifications)	Adjusted Figures (audited figures after adjusting for qualifications)
I	1	Turnover/ Total Income	N.A.	N.A.
	2	Total Expenditure	N.A.	N.A.
	3	Net Profit (Loss)	N.A.	N.A.
	4	Earnings Per Share	N.A.	N.A.
	5	Total Assets	N.A.	N.A.
	6	Total Liabilities	N.A.	N.A.
	7	Net Worth	N.A.	N.A.
	8	Any Other Financial Items(s) (as felt appropriately the management)	N.A.	N.A.
II		Audit Qualification (each audit qualification separately)		
	a	Details of Audit Qualifications:	N.A.	
	b	Type of Audit Qualifications: Qualified opinion / Disclaimer of opinion/ Adverse opinion	Unmodified	

**CHANDAN HEALTHCARE LIMITED**

Reg. Off. Add: Biotech Park, Sector-G, Jankipuram, Kursi Road, Lucknow-226021

CIN: U85110UP2003PLC193493

TELNO.: -8069366666 Email: secretarial@chandan.co.in

www.chandandiagnostic.com

	c	Frequency of qualifications: Whether appeared first time /repetitive / since how long continued	N.A.
	d	For Audit Qualification(s) where the impact is quantified by the auditor, management's Views:	N.A.
	e	For Audit Qualifications(s) where the impact is not qualified by the auditor	(i) N.A.
			(ii) N.A.
		(i) Management's estimation on the impact of audit qualification.	N.A.
		(ii) If management is unable to estimate the impact, reason for the same.	N.A.
		(iii) Auditor's Comments on (i) or (ii) above:	N.A.
III		Signatories:	
		<ul style="list-style-type: none">CEO/ Managing Director	
		<ul style="list-style-type: none">CFO	



CHANDAN HEALTHCARE LIMITED

Reg. Off. Add: Biotech Park, Sector-G, Jankipuram, Kursi Road, Lucknow-226021

CIN: U85110UP2003PLC193493

TELNO.: -8069366666 **Email:** secretarial@chandan.co.in

www.chandandiagnostic.com

		<ul style="list-style-type: none">Audit Committee Chairman	
		<ul style="list-style-type: none">Statutory Auditor	
		Place:	Lucknow
		Date:	27/05/2025





CHANDAN HEALTHCARE LIMITED

Reg. Off. Add: Biotech Park, Sector-G, Jankipuram, Kursi Road, Lucknow-226021

CIN: U85110UP2003PLC193493

TELNO.: -8069366666 Email: secretarial@chandan.co.in

www.chandandiagnostics.com

Date: May 27, 2025

To,
The Listing Department
National Stock Exchange of India Ltd.
Exchange Plaza, Plot no. C/1, G Block,
Bandra- Kurla Complex, Bandra (East),
Mumbai - 400 051

Symbol: CHANDAN

Ref: Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Sub: Appointment of Internal Auditor and Cost Auditor for the financial year 2025-26

Dear Sir/Madam,

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations"), this is to inform that the Board of Directors of Chandan Healthcare Limited in their meeting held on May 27, 2025 (commenced at 12.30 pm(IST) & closed at 08:45 pm) inter-alia considered and approved the followings:

1. Re-appointment of Internal Auditor: Re-appointment of M/s. Renu Agrawal & Co., Chartered Accountants, as an Internal Auditor of the Company, as per the recommendation of the Audit Committee, to conduct the Internal Audit for the Financial Year 2025-26.
2. Re-appointment of Cost Auditor: Re-appointment of M/s. Rahul Jain & Associates, Cost Accountants, as the Cost Auditors of the Company, as per the recommendation of the Audit Committee, to conduct the Cost Audit for the Financial Year 2025-26.

The disclosures required pursuant to Regulation 30 read with Para A of Part A of Schedule III of the SEBI Listing Regulations and SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, regarding the aforesaid reappointments of Internal Auditor and Cost Auditor are enclosed as **Annexure I & II** respectively.

The above disclosures are available on the website of the Company at www.chandandiagnostics.com

The Board meeting commenced at 12:30 PM and concluded at 08:45 P.M.

We request you to kindly take the same on record.

Yours sincerely,
For Chandan Healthcare Limited

Rajeev Nain
Company Secretary & Compliance Officer

Encl: as above



CHANDAN HEALTHCARE LIMITED

Reg. Off. Add: Biotech Park, Sector-G, Jankipuram, Kursi Road, Lucknow-226021

CIN: U85110UP2003PLC193493

TELNO.: -8069366666 Email: secretarial@chandan.co.in

www.chandandiagnostic.com

Annexure I

Disclosures required pursuant to Regulation 30 read with Para A of Part A of Schedule III of the SEBI Listing Regulations and SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 - Appointment of M/s. Renu Agrawal & Co., Chartered Accountants as the Internal Auditor of the Company

S. No.	Particulars	Details
1	Name & Details	M/s. Renu Agrawal & Co. (FRN No. 018547C) Chartered Accountants Mobile : +91-880044668 E-Mail : carajatgarg@gmail.com ; rajat@raac.in Address: Unit No. 302, Vipul Trade Centre, Sector 48, Sohna Road, Gurgaon-122018
2	Reason for Change viz., appointment/re-appointment, resignation, death or otherwise	Re-appointment
3	Date of Appointment	Reappointed for F.Y. 2025-26
4	Term of Appointment/Re-appointment	1 Year
5	Brief Profile	M/s. Renu Agrawal & Co. is a firm of Chartered Accountants in India. The Firm provides services in the fields of audit and assurance, tax and regulatory, transaction advisory and consulting keeping in mind the regulatory and commercial environment within which the Firm's clientele operate.
6	Disclosure of relationships between directors (in case of appointment of a director).	NA



CHANDAN HEALTHCARE LIMITED

Reg. Off. Add: Biotech Park, Sector-G, Jankipuram, Kursi Road, Lucknow-226021

CIN: U85110UP2003PLC193493

TELNO.: -8069366666 Email: secretarial@chandan.co.in

www.chandandiagnostic.com

Annexure II

Disclosures required pursuant to Regulation 30 read with Para A of Part A of Schedule III of the SEBI Listing Regulations and SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 - Appointment of M/s. Rahul Jain & Associates, Cost Accountants as Cost Auditor of the company

S. No.	Particulars	Details
1	Name & Details	M/s. Rahul Jain & Associates (FRN No. 101515) Cost Auditors Mobile : +91-9810720116 E-Mail : cmarahuljain@gmail.com Address: 606, Signature Global Mall Vaishali Sector-3, Ghaziabad, UP – 201010
2	Reason for Change viz., appointment/re-appointment, resignation, death or otherwise	Re-Appointment
3	Date of Appointment	Reappointed for F.Y. 2025-26
4	Term of Appointment/Re-appointment	1 Year
5	Brief Profile	M/s. Rahul Jain & Associates is a Partnership firm of Cost Accountants having a track record of providing expert services in Cost Management Accountancy. The Firm provides profession services like, Cost Audit, Costing Systems, Cost Study and analysis, etc.
6	Disclosure of relationships between directors (in case of appointment of a director).	NA



CHANDAN HEALTHCARE LIMITED

Reg. Off. Add: Biotech Park, Sector-G, Jankipuram, Kursi Road, Lucknow-226021

CIN: U85110UP2003PLC193493

TELNO.: -8069366666 Email: secretarial@chandan.co.in

www.chandandiagnostic.com

Date: May 27, 2025

To,
The Listing Department
National Stock Exchange of India Ltd.
Exchange Plaza, Plot no. C/1, G Block,
Bandra- Kurla Complex, Bandra (East),
Mumbai - 400 051

Symbol: CHANDAN

Ref: Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Sub: Revision in remuneration of Managing Director

Dear Sir/Madam,

Pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of **Chandan Healthcare Limited** at its meeting held on 27.05.2025, has approved the **reduction** in remuneration of Mr. Amar Singh, Managing Director of the Company, with effect from May 01, 2025.

The details as required are provided below:

1. **Name of the Director:** Amar Singh
2. **Designation:** Managing Director
3. **Nature of Change:** Reduction in remuneration
4. **Effective Date:** 01.05.2025
5. **Reason for change:** Company wide freezing in salary

The above disclosures are available on the website of the Company at www.chandandiagnostic.com

The Board meeting commenced at 12:30 PM and concluded at 08:45 P.M.

We request you to kindly take the same on record.

Yours sincerely,
For Chandan Healthcare Limited

Rajeev Nain
Company Secretary & Compliance Officer



CHANDAN HEALTHCARE LIMITED

Reg. Off. Add: Biotech Park, Sector-G, Jankipuram, Kursi Road, Lucknow-226021

CIN: U85110UP2003PLC193493

TELNO.: -8069366666 Email: secretarial@chandan.co.in

www.chandandiagnostic.com

Date: May 27, 2025

To,
The Listing Department
National Stock Exchange of India Ltd.
Exchange Plaza, Plot no. C/1, G Block,
Bandra- Kurla Complex, Bandra (East),
Mumbai - 400 051

Symbol: CHANDAN

Ref: Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Sub: Revision in remuneration of Managing Director

Dear Sir/Madam,

Pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of **Chandan Healthcare Limited** at its meeting held on 27.05.2025, has approved the **reduction** in remuneration of Mrs. Asmita Singh, Managing Director of the Company, with effect from May 01, 2025.

The details as required are provided below:

1. **Name of the Director:** Asmita Singh
2. **Designation:** Managing Director
3. **Nature of Change:** Reduction in remuneration
4. **Effective Date:** 01.05.2025
5. **Reason for change:** Company wide freezing in salary

The above disclosures are available on the website of the Company at www.chandandiagnostic.com

The Board meeting commenced at 12:30 PM and concluded at 08:45 P.M.

We request you to kindly take the same on record.

Yours sincerely,
For Chandan Healthcare Limited

Rajeev Nain
Company Secretary & Compliance Officer



MSNT & ASSOCIATES LLP

CHARTERED ACCOUNTANTS

27th May, 2025.

To,
The Manager – Listing Department.
National Stock Exchange of India Limited
Exchange Plaza, Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (East), Mumbai – 400 051.

Reference: - Chandan Healthcare Limited
NSE Code:-CHANDAN
ISIN: INE0B2N01016

Sub: Statement of Deviation or Variation of funds under Regulation 32 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations) for the half year ended on 31st March, 2025.

Dear Sir,

Pursuant to Regulation 32 of the SEBI Listing Regulations and SEBI Circular No. CIR/CFD/CMD1/162/2019 dated December 24, 2019, Please find enclosed herewith a statement in this regard.

The aforesaid statement has been reviewed by the Audit Committee and taken on record by the Board at their respective meetings held on 27th May, 2025.

This is for your information and records please.

Please take the above information on record.

Thanking You,

Yours Faithfully

For Chandan Healthcare Limited



📍 : **Head Office:** - A-40, I-Thum, Tower-B, 10th Floor, Unit No. 1033, Sector 62, Noida-201005.
Branch Office: - 239, Satra Plaza, Sector-19 D, Palm Beach Road, Vashi, Navi Mumbai-400703.
☎ : CA Saurabh Tyagi: 7718802884, CA Navodit Tyagi: 9167436404, CA Manoj Modi: 9022059201.
✉ : saurabh@msnt.in navodit@msnt.in manoj@msnt.in

Annexure 1-Statement of Deviation or Variation in Utilization of Funds Raised

Name of the Listed Entity	Chandan Healthcare Limited
Mode of Raising Fund	Initial Public Offer
Date of raising Fund	17th Feb, 2025
Amount Raised (Rs. in Lakhs)	7041.94
Report filed for the quarter/half year	31st March, 2025
Monitoring Agency	Not Applicable
Monitoring Agency Name, if applicable	Not Applicable
Is there a Deviation/Variation in use of funds raised	No
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders	--
If yes, Date of shareholder approval	--
Explanation for Deviation/Variation	--
Comments of the Audit Committee after review	
Comments of the Auditors, if any	

Objects for which funds have been raised and where there has been a deviation, in the following table:

1. Funding capital expenditure requirements for setting up of a flagship diagnostic centre in Jankipuram, Lucknow, Uttar Pradesh.

Original Object	Modified Object, if any	Original Allocation (Amount in Lakhs)	Modified Allocation, if any	Funds Utilised till 31.03.2025	Amount of Deviation/Variation for the quarter according to applicable object	Remarks if any
				(Amount in Lakhs)		
Funding capital expenditure requirements for setting up of a flagship diagnostic centre in Ashiyana, Lucknow, Uttar Pradesh.						
Funding capital expenditure towards installation of plant & machinery in our New premises along with required, electric and fabrication work	NO	710.11	0	629.41	0	Partially Utilised till March, 2025 quarter
Funding capital expenditure requirements for setting up of a flagship diagnostic centre in Ayodhya, Uttar Pradesh.						
Funding capital expenditure towards installation of plant & machinery in our New premises along with required, electric and	NO	710.11		216.074	0	Partially Utilised till March, 2025 quarter



fabrication work						
Funding capital expenditure requirements for setting up of a flagship diagnostic centre in Jankipuram , Lucknow, Uttar Pradesh.						
Funding capital expenditure towards installation of plant & machinery in our New premises along with required civil, electric and fabrication work	NO	3281.58	0	490.60		0
General corporate purposes	NO	1672.45	0	1,480.05		0
Issue related expenses	NO	670.27	0	637.52		0

Deviation or variation could mean:

Deviation in the Objects or purposes for which the funds have been raised or

Deviation in the amount of funds actually utilized as against what was originally disclosed or

Change in terms of a contract referred to in the funds raising documents I.e., prospectus, Letter of Offer

For MSNT & ASSOCIATES LLP

Chartered Accountants

Firm Registration No.018542C/C400322



Navodit Tyagi

Partner

Membership No.-533375

UDIN No: 25533375BMOKNO7403

Place: Noida

Date: 27/05/2025

